Summary

Initiate at Sell with a $298 target as peer valuation caps the recovery

InitiationBy Penmark Team
UNHSell$297.81-15%
Page 1 of 28
Equity Research | Initiation of coverage | United States
Managed Care & Health Services | Coverage: Initiated | Published 20 November 2026
Penmark Team | research@penmarkresearch.com
UnitedHealth Group Incorporated (NYSE: UNH)

Initiate at Sell with a $298 target as peer valuation caps the recovery

Rating
Initiation · Low conviction
Sell
12-month target
$297.81
Price, 18 Nov 26
$349.91
Price return
−14.9%
Total return
−12.2%
Bull case
$428.07
Bear case
$168.75

We initiate on UnitedHealth Group at Sell (low conviction) with a $298 target (−12% total return). We price at the 18 Nov close of $349.91; at the 19 Nov close of $330.48 the return is −7%, inside our Hold band (p23). UNH runs UnitedHealthcare (UHC) and Optum’s care, IT and pharmacy units. Buyers pay 14.9x 2027 adjusted earnings per share (EPS), overpricing recovery in the medical care ratio (MCR, premiums spent on care).

  • Peer multiple parity cuts $95 a share. Restating peers for UNH’s 13% growth and 22% return on equity (ROE) gives an 11.4x price-to-earnings (P/E) median vs 14.9x paid.
  • Margins reach 6.3% in FY27E, 2.3pp below the historical median. The V28 risk-model phase-in and >11% commercial trend hold UHC margins near 4% vs 6.4% implied.
  • Audit clawbacks cost $4 a share in base. Full Risk Adjustment Data Validation (RADV) recovery by the Centers for Medicare & Medicaid Services (CMS) under its proposed rule (CMS-6098-P, known as CRUSH) costs $12/sh vs a $62 drop.

What the market is missing. Our FY27E EPS is 1% above consensus; at 11.5x, $350 needs $31 EPS or a 6.4% UHC margin vs our 4.1%.

Catalysts. Dec investor update, 19 Jan CRUSH comments, 26 Jan Q4 results and the 2028 rate notices (late Jan, 6 Apr).

Valuation and target. Base value is $266 at 11.5x FY27E EPS less RADV; 25/50/25 bear/base/bull weights give $282, rolled to $298.

Risks. Unpriced trend (−$41/sh) and Department of Justice (DOJ) Medicare Advantage (MA) coding probes (−$24/sh) lead downside.

Exhibit 1: Earnings rebound 67% from FY25A to FY28E, yet UNH trades at 14.9x FY27E EPS vs 12.7x at our target
Dec YE, US$bnFY24AFY25AFY26EFY27EFY28E
Revenue400.3447.6449.8464.8487.2
Growth y/y+7.7%+11.8%+0.5%+3.3%+4.8%
Adj. op. earnings34.421.726.729.533.2
Adj. op. margin8.6%4.9%5.9%6.3%6.8%
Adj. net income25.714.918.720.923.6
Adj. EPS ($)27.6616.3520.7323.5227.35
Growth y/y+10.1%−40.9%+26.8%+13.4%+16.3%
FCF after SBC19.715.123.221.024.0
At $349.91, 18 NovFY24AFY25AFY26EFY27EFY28E
P/E (adjusted)12.7x21.4x16.9x14.9x12.8x
P/E (GAAP)22.6x26.4x17.8x15.7x13.4x
Price / book3.3x3.2x3.0x2.8x2.7x
FCF yield (after SBC)6.1%4.7%7.3%6.7%7.9%
Dividend yield2.3%2.5%2.6%2.7%2.9%
Adjusted ROE26.5%15.0%18.4%19.7%21.6%
Medical care ratio85.5%89.1%87.5%n.a.n.a.
P/E at $297.81 target10.8x18.2x14.4x12.7x10.9x

Source: SEC filings; Yahoo Finance; Penmark model. P/B: avg. sh FY24A–25A, YE sh FY26E–28E. FCF = free cash flow; SBC = share-based compensation.

Our $266 base value and $298 target leave more downside than upside

Exhibit 3: Scenario values rolled forward 12 months weight to our $298 target
$100$200$300$400$500Jan-26Jul-26Jan-27Jul-27ActualEstimatesPrice $350Bull $451 (+29%)Base $281 (−20%)Bear $178 (−49%)Target $298 (−15%)

Source: Yahoo Finance; Penmark Research valuation model. Spot values at 18 Nov 2026 rolled forward 12m at 5.46% (cost of equity less next-12m dividend yield).

Spot scenario values and 12m target basis
Bull$428.07+22.3%25% prob.

FY27E adj. EPS $26.75 at 16.0x best-peer P/E; UHC margin 4.6%, Optum Health 5.0%, Medicare & Retirement (M&R) +7.0%; RADV vacated ($0).

Base$266.36−23.9%50% prob.

FY27E adj. EPS $23.52 at 11.5x peer-median P/E less $4.08 RADV (35% upheld); UHC margin 4.1%, Optum Health 4.0%.

Bear$168.75−51.8%25% prob.

FY27E adj. EPS $17.18 at 10.5x lowest-peer P/E less $11.66 full RADV (100% upheld); UHC margin 3.0%, Optum Health 2.0%.

12m target (from $282.39 weighted)$297.81−12.2% total return = Sell
Downside exceeds upside$103$181 bear loss vs $78 bull gain
Exhibit 4: Adjusted operating profit rebounds 53% from FY25A to FY28E
Income stmt, $bnFY24AFY25AFY26EFY27EFY28E
Revenue400.3447.6449.8464.8487.2
Adj. EBITDA38.526.131.033.937.8
Adj. op. earnings34.421.726.729.533.2
GAAP op. earnings32.319.027.129.533.2
Interest & sub. loss(12.2)(4.3)(4.1)(3.8)(3.8)
Income tax & NCI(5.7)(2.6)(5.3)(5.8)(6.7)
Net inc., adjusted25.714.918.720.923.6
Net inc., GAAP14.412.117.719.822.6
Exhibit 5: Annual FCF after SBC averages $23bn across FY26E–FY28E
Cash flow, $bnFY24AFY25AFY26EFY27EFY28E
Net inc., GAAP14.412.117.719.822.6
D&A & working cap.9.87.610.15.15.5
Operating cash flow24.219.727.824.928.1
Capital expenditure(3.5)(3.6)(3.8)(4.0)(4.1)
Less: reported SBC(1.0)(1.0)(0.8)0.00.0
FCF after SBC19.715.123.221.024.0
Dividends paid(7.5)(7.9)(8.3)(8.5)(8.8)
Share repurchases(9.0)(5.5)(5.0)(7.0)(12.2)
Exhibit 6: Debt-to-capital falls to 40% in FY27E; cash and investments hit $88bn
Balance sheet, $bnFY24AFY25AFY26EFY27EFY28E
Cash & investments81.582.485.988.391.3
Receivables22.423.020.721.422.4
Goodwill & PP&E160.1164.7169.4169.0168.5
Total assets298.3309.6312.5315.1318.7
Med. costs payable34.239.339.340.742.6
Total debt76.978.474.371.371.3
Cash & inv. less debt4.64.011.617.020.0
Equity98.3100.1103.9108.2109.8
Exhibit 7: Buybacks retire 48m shares from FY25A to FY28E, lifting EPS
Per share & KPIsFY24AFY25AFY26EFY27EFY28E
Avg. diluted shares (m)929911904888863
EPS, adjusted ($)27.6616.3520.7323.5227.35
EPS, GAAP ($)15.5113.2319.6222.3426.20
Dividend per share ($)8.118.699.139.519.99
FCF after SBC / sh ($)21.1916.5825.6723.6127.80
Book value / sh ($)105.78109.87115.71123.24129.54
UHC margin5.4%2.8%3.7%4.1%4.4%
Optum Health margin7.5%2.2%3.0%4.0%5.0%

Source: SEC 10-K and 8-K filings; Penmark Research model. EBITDA = earnings before interest, tax, depreciation and amortisation (D&A); NCI = noncontrolling interests; SBC = share-based compensation (deducted separately in FY24A–9M26A; forecast basis treats SBC as cash inside operating cash flow); book value per share uses average shares in FY24A–FY25A and year-end shares in FY26E–FY28E; model treats investments as backing reserves ($45.8bn net debt at 3Q26).

Adjusted ROE rebuilds to about 20% in FY27E; our EPS is 1% above consensus

Exhibit 8: Operating margin recovers nearly 2pp from FY25A to 7% in FY28E
Growth, margins (%)FY24AFY25AFY26EFY27EFY28E
Growth y/y
Revenue+7.7%+11.8%+0.5%+3.3%+4.8%
Adjusted EBITDA+5.9%−32.3%+18.7%+9.6%+11.5%
Adj. op. earnings (EBIT)+6.3%−36.9%+23.1%+10.4%+12.5%
Adjusted EPS+10.1%−40.9%+26.8%+13.4%+16.3%
Dividend per share+11.2%+7.2%+5.1%+4.2%+5.0%
Margins and coverage
Medical care ratio (MCR)85.5%89.1%87.5%n.a.n.a.
Adj. EBITDA margin9.6%5.8%6.9%7.3%7.8%
Adj. operating margin8.6%4.9%5.9%6.3%6.8%
FCF after SBC margin4.9%3.4%5.2%4.5%4.9%
Adj. EBITDA / interest9.9x6.5x8.0x8.9x9.8x
Capex / revenue0.9%0.8%0.8%0.8%0.8%
Exhibit 9: At $350 UNH trades at 15x FY27E EPS vs 13x at our target
Ratios and valuationFY24AFY25AFY26EFY27EFY28E
Returns and capital structure
Adjusted ROE (avg. eq.)26.5%15.0%18.4%19.7%21.6%
GAAP ROA (avg. assets)4.9%4.0%5.7%6.3%7.1%
Adj. ROCE (nopat / cap.)15.8%10.7%12.1%13.2%14.7%
Total debt / capital43.9%43.9%41.7%39.7%39.4%
Cash & inv. less debt ($bn)+4.6+4.0+11.6+17.0+20.0
Valuation at $349.91 current price
P/E (adjusted)12.7x21.4x16.9x14.9x12.8x
P/E (GAAP)22.6x26.4x17.8x15.7x13.4x
Price / book3.3x3.2x3.0x2.8x2.7x
FCF yield (after SBC)6.1%4.7%7.3%6.7%7.9%
Dividend yield2.3%2.5%2.6%2.7%2.9%
P/E at $297.81 target10.8x18.2x14.4x12.7x10.9x

Source: SEC filings; Penmark Research model. ROA = return on assets; ROCE = return on capital employed. Price / book uses average diluted shares in FY24A–FY25A and year-end shares in FY26E–FY28E. Our model treats investments as backing insurance reserves (net debt is $45.8bn at 3Q26 excluding regulated investments).

Exhibit 10: Our EPS estimates sit about 1% above consensus in FY26E and FY27E
US$m / US$ per share3Q26A4Q26EFY26EFY27E
Revenue ($m)
Penmark / actual112,694113,400449,847464,769
Consensusn.d.110,453446,900Not found
Prior-year period113,161113,215447,567449,847
Diff. vs consensusn.d.+2.7%+0.7%n.d.
Growth y/y (Penmark)−0.4%+0.2%+0.5%+3.3%
Adjusted EPS ($)
Penmark / actual4.692.3920.7323.52
Consensusn.d.2.2920.5923.29
Prior-year period2.922.1116.3520.73
Diff. vs consensusn.d.+4.3%+0.7%+1.0%
Growth y/y (Penmark)+60.6%+13.2%+26.8%+13.4%

Source: Q3 FY26 8-K; clearank.com consensus (12 Nov 2026; 4Q26E implied by FY26E less 9M actual; FY27E revenue consensus not found).

Exhibit 11: Adjusted EPS recovers 67% from $16 in FY25A to $27 in FY28E
Consensus$0$10$20$30FY22AFY23AFY24AFY25AFY26EFY27EFY28EActualEstimates$22.19$25.12$27.66$16.35$20.73$23.52$27.35

Source: Company filings (A); clearank.com consensus; Penmark Research (E).

UNH trades at a 61% raw P/E premium to core managed-care peers despite similar growth

Exhibit 12: On company 2027 outlooks, UNH trades at 15.1x vs 9.4x peer median
FY27E, at 18 Nov priceUNHPeersDiff.
Valuation (company 2027 outlook basis)
P/E, FY27E raw (outlook)15.1x9.4x+60.6%
P/E, restated for UNH g & ROE15.1x11.4x+32.7%
Price / book (FY25A YE)3.4x1.8x+84.2%
Forward dividend yield2.7%2.2%+0.5pp
Growth, margins and returns
FY27E EPS growth (outlook)13.0%12.0%+1.0pp
Forward ROE (FY27E / BV)22.4%15.3%+7.1pp
Consolidated op. margin (9M26)6.9%4.0%+2.9pp
UHC margin (9M26)4.8%4.0%+0.8pp
Raw P/E, all 6 peers median15.1x13.2x+14.6%
Restated P/E incl. CNC15.1x13.6x+10.8%

Source: Company outlooks; Penmark Research model (ELV, CI, CVS core; FY25A P/B 3.4x on YE BVPS $103.30 vs 3.2x avg. sh in Ex. 1 & 9; peer margin med. 4.0%: ELV 4.6%, CI 4.0%, HUM 3.5%); Yahoo Finance.

Exhibit 13: Five catalysts from Dec 2026 to Apr 2027 test guidance and CMS
  • Dec 2026Investor update sets FY27 EPS framework (≥$23.17 floor).
  • 19 Jan 27CRUSH comments close on payment year (PY) 2018–27 RADV.
  • 26 Jan 27Q4 results & FY27 guide; our $23.52 vs $23.29 Street.
  • Late Jan2028 MA Advance Notice sets draft rates & coding rules.
  • 6 Apr 272028 MA Final Notice sets rates before June bids; Q1 MCR mid-April.

Source: CMS docket CMS-6098-P; company calendar; Penmark Research.

Exhibit 14: Unpriced trend and DOJ coding lead downside; bull case is upside
  • Trend outruns pricing. UHC margin falls to 3.0%. 20% prob.; −$40.78/sh.
  • DOJ MA coding probe. Settlement cuts P/E to 10.5x. 20% prob.; −$23.52/sh.
  • CRUSH RADV upheld. Full 10-yr rule adds $7.58/sh. 35% prob.; −$7.58/sh.
  • Bull recovery. $26.75 EPS at 16.0x, $0 RADV. 25% bull; +$161.71/sh.
The thesis is invalidated ifQ4 guide sets FY27E EPS >$24.80 or our base multiple tops 12.1x (either gives Hold); we watch MCR <86.5%.

Source: Penmark Research model.

Exhibit 15: Forward P/E of 15.0x sits 1.4 SD below its 18.5x five-year mean
12.5x15.0x17.5x20.0x22.5x25.0x202220242026Mean 18.5x+1 SD 20.9x−1 SD 16.0x+2 SD 23.3x−2 SD 13.6x15.0x, −1.4 SD

Source: Yahoo Finance; company filings; Penmark Research (15.0x on consensus FY27E EPS). Standard deviation (SD) bands around 5-year monthly mean.

Exhibit 16: UNH trades at 3.4x FY25A book, well above the peer ROE line
1x2x3x4x10.0%12.5%15.0%17.5%20.0%22.5%Price / book, FY25AForward ROE, FY27EUNHELVCICVSCNCHUMMOHR² 0.16, n=6

Source: Signals; Yahoo Finance; Penmark Research (FY25A year-end BVPS $103.30; 18 Nov 2026). Ordinary least squares (OLS) fit across 6 US managed-care peers ex-UNH (R² = 0.16).

PART 1 · SUMMARY · 3 THE THESIS IN CHARTS

MCR swings drove the derating, and peer multiple parity leaves 24% downside to base value

Exhibit 17: The share price fell as MCR rose through 2025
Medical care ratio (left)Period-end share price (right)80%85%90%95%$200$300$400$500$6004Q241Q252Q253Q254Q251Q262Q263Q2688.4%

Source: Company 8-K releases; Yahoo Finance; Penmark model (2Q26 MCR n.a. in model). Quarterly correlation r = −0.26 (seven plotted quarters with MCR, 4Q24–3Q26).

Exhibit 18: Peer multiple compression cuts $95 a share, driving our $266 base value
$0$100$200$300$400Price, 18NovFY27E EPSbeatRADV 35%vs 100%Peer P/E11.5xBase P/Evalue$349.91+$3.52+$7.58−$94.65$266.36

Source: Penmark Research valuation model.

Exhibit 19: Consolidated margin reaches 7.5% by FY30E, below the 8.7% historical median
Consolidated adj. marginUHC margin2%4%6%8%10%FY20AFY22AFY24AFY26EFY28EFY30EActualEstimates7.5%4.9%FY20–25 med. 8.65%

Source: Company filings (A); Penmark Research model (E).

Exhibit 20: Optum contributes 50% of FY27E operating profit as UHC rebuilds
UnitedHealthcareOptum RxOptum InsightOptum Health$0bn$10bn$20bn$30bn$40bn$50bnFY24AFY25AFY26EFY27EFY28EFY29EFY30EActualEstimates$34.4bn$21.7bn$26.7bn$29.5bn$33.2bn$37.1bn$40.5bn

Source: Company filings (A); Penmark Research model (E).

Exhibit 21: Trailing P/B of 3.0x on 3Q26 equity sits 1.3 SD below its 4.7x five-year mean
2x4x6x8x202220242026Mean 4.7x+1 SD 6.0x−1 SD 3.4x+2 SD 7.3x−2 SD 2.2x3.0x, −1.3 SD

Source: Yahoo Finance; company filings (3.0x on 3Q26 reported equity of $104.1bn / 902m diluted sh). Bands show ±1 and ±2 SD around 5-year mean.

Exhibit 22: P/E derating cost 28pp over five years, outweighing EPS growth in total return
EPS growthMultiple changeDividendsNet−40%−20%0%+20%1-year3-year5-yearNet +14.5%Net −30.5%Net −14.8%

Source: Yahoo Finance; company filings; Penmark Research (price and dividend returns to 18 Nov 2026).

PART 1 · SUMMARY · 4 KEY DEBATES

Three debates separate our $266 value from the $350 price; the P/E debate dominates

Exhibit 23: Sequential value bridge shows the $95/sh multiple debate outweighs small EPS and RADV offsets
DebateMarket viewPenmark viewEvidenceWhat changes our viewResolves
Peer multiple gap (−$94.65/sh) Integrated compounder worth 14.9x FY27E EPS, or 15.5x with RADV added back. 11.5x restated peer median (ELV, CI, CVS) captures federal policy risk. 9M26 UHC margin (4.8%) sits near ELV (4.6%); DOJ MA coding probe and V28 cap re-rating. Our base multiple above 12.1x (Hold). We also watch for a DOJ coding resolution. Apr 2027
Margin normalisation (+$3.52/sh on FY27E EPS) Consensus $23.29 FY27E EPS; price implies 6.4% UHC margin at 11.5x. $23.52 FY27E EPS; consolidated margin reaches 7.5% in FY30E (~7.7% from FY31E) vs 8.65% median. Commercial trend >11%, 100% pharmacy benefit manager (PBM) rebate pass-through by 2028, Optum Health value-based care (VBC) rebuild. FY27E EPS guided above $24.80 (Hold) or the 8.65% historical median margin (Buy). We also watch MCR below 86.5%. Jan–Jul 27
RADV clawback rule (+$7.58/sh vs 100% priced) Two-day $62.11/sh drop priced full CRUSH RADV extrapolation plus policy contagion. 35% probability upheld = $4.08/sh expected PV ($11.66/sh at 100% upheld). CMS $9bn/yr industry estimate × 21.1% UNH reported MA enrolment share (vs 26% KFF all-MA share) over 10 yrs; 5th Circuit appeal. CMS withdraws PY2018–PY2027 extrapolation (bull +$4.08/sh) or wins full enforcement. Jan / 2H27

Source: Penmark Research model. Sequential bridge from $349.91 price to $266.36 base value (−$83.55/sh net). 15.5x = ($349.91 + $12 RADV) / consensus FY27E EPS.

Exhibit 24: The valuation gap sits in the 11.5x P/E and 4.1% UHC margin, not EPS
Price / StreetPenmark baseFY27E P/E multiple (x)FY27E UHC margin (%)Implied DCF discount rate(%)FY27E Adj. EPS ($)11.514.94.16.410.713.023.323.5

Source: Penmark Research model (13.0% is the discounted cash flow (DCF) discount rate at base P/E value vs 8.2% capital asset pricing model (CAPM) cost of equity).

How the debates map to our thesis

Our Sell call rests on valuation discipline rather than an earnings miss. Our FY27E adjusted EPS sits 1% above consensus, adding about $4 a share.

Our 35% RADV weight adds $8 a share vs full enforcement. Repricing to 11.5x from 15.5x (consensus EPS, full $12 RADV cost added back) deducts $95 a share.

What it means for valueEven at $0 RADV liability and $24.69 EPS (5% above base), 11.5x values UNH at $283.96, well below $350.
Exhibit 25: Five regulatory and earnings milestones resolve the debates by late 2027
Dec 2026Investor outlookInitial FY27 EPS framework19 Jan 27CRUSH comments closeCMS-6098-P docketcloses26 Jan 274Q26 results & 27 guideMA enrolment & MCR resetApr 20272028 MA Final NoticeCMS rate & risk-model rule2H 2027Final RADV / 5th Cir.Extrapolation legal test

Source: CMS docket CMS-6098-P; company calendar; Penmark Research.

PART 2 · THE BUSINESS · 5 THE STORY

UnitedHealthcare is Optum’s biggest customer, worth $168bn a year

UnitedHealth Group serves 48 million medical members and treats patients, dispenses drugs and routes claims across Optum. Its engine is an internal bridge where insurer spending feeds its own clinics and pharmacies. Federal auditors now scrutinise that bridge.

52 yrsRoots to 1974 (inc. 1977, MN)
48.3mUHC medical members (3Q26)
$447.6bnFY25A consolidated revenue
165,000Clinical staff inside 390k total
$315.6bnMarket cap at $349.91

Every morning across the US, a senior in a UnitedHealthcare Medicare Advantage plan visits an Optum clinic and fills a prescription. No cash changes hands at the desk, yet three ledgers move at once. The insurer collects a monthly federal premium, pays its clinic a capitated budget and routes the drug claim through Optum Rx, its own PBM.

How the money comes in

Monthly premiums arrive up front, funding $87bn of cash and investments before claims settle. In FY25A, UnitedHealthcare generated $345bn and Optum $271bn; cancelling $168bn of internal billings left $448bn of consolidated revenue. At the FY25A trough, claims and costs took 95.1 cents per dollar, leaving $22bn of operating profit and $15bn of free cash flow.

Where the story turns

After unifying Optum in 2011 and buying Change Healthcare for $14bn in October 2022, vertical integration looked durable. In 2025, the V28 risk-model phase-in met rising outpatient and drug bills, lifting the MCR to 89.1% and cutting adjusted EPS by 41% to $16. Stephen Hemsley returned as CEO in May 2025. UNH has shed 1.3m commercial risk lives since December 2024 and repriced 2026 plans.

Why it works, and what could break it

Switching networks disrupts doctors and drug lists, supporting a 22% forward ROE. Yet the bridge between insurer and clinic faces the RADV clawback rule, DOJ MA coding probes and commercial trend above 11%, driving margin normalisation and the peer multiple gap.

$168bnFY25A intersegment revenue
More than a third of UnitedHealthcare’s medical and pharmacy spend stays inside Optum’s clinics, pharmacies and software.That integration rules out a sum-of-the-parts valuation and ties $95 a share of value directly to managed-care peer multiples.
Exhibit 26: One Medicare Advantage member, start to finish: from federal premium to a 2%–4% target MA margin
1 · Enrols in UHC plan
~$1,860/moMedicare & Retirement revenue per MA member (7.6m MA lives).
2 · Uses Optum Health
92mTotal consumers served across Optum Health (3Q26).
3 · Fills via Optum Rx
393m3Q26 adjusted scripts managed across retail and mail.
4 · What UHC keeps
2–4¢ / $1Target MA margin (vs 6.3% FY27E group operating margin).

Source: SEC FY25 10-K and Q3 FY26 8-K; Penmark Research model. Tie to the stock: investors pay 14.9x for this platform (15.1x on the 2027 floor) vs a 9.4x raw core-peer median.

PART 2 · THE BUSINESS · 5 HOW THE COMPANY MAKES MONEY

Vertical integration links $345bn of health plans to $271bn of Optum care and pharmacy

Exhibit 27: Seven milestones turned a 1974 Minnesota HMO manager into a $448bn healthcare platform
1974
Charter Med foundedStarted in Minnesota to manage health maintenance organisation (HMO) plans.Predecessor firm
1984
Initial public offeringTraded over the counter in 1984 before moving to the NYSE in 1991.OTC 1984; NYSE 91
2011
Optum brand unifiedMerged clinics, analytics and pharmacy services under one arm.4 segments set
2022
Change HealthcareClosed in Oct 2022 after a federal court rejected the DOJ’s challenge.$13.8bn deal value
2025
MCR & CEO resetFY25A MCR hit 89.1%; Stephen Hemsley returned as CEO in May.$16.35 adj. EPS
Oct 26
3Q26 guidance raise3Q26 MCR eased to 88.4%; FY26 EPS floor raised a third time.≥$20.50 floor
Nov 26
CRUSH rule shockCMS proposed PY2018–PY2027 RADV audit extrapolation; stock fell 15%.$349.91 price
Company milestoneStructural turning pointModel cut-off (18–20 Nov 2026)

Source: SEC FY25 10-K and 2026 DEF 14A; Reuters; Penmark Research model.

Exhibit 28: In FY25A, $345bn of UHC and $271bn of Optum revenue netted $168bn of transfers into $22bn of profit

1 · Customers

CMS (Medicare)
8.45m MA lives FY25A; $171.3bn M&R rev.
States (Medicaid)
7.38m Community & State (C&S) lives; $94.4bn rev.
Employers & Ind.
8.17m risk + ASO fees; $79.2bn rev.
External payers/prov.
$102.7bn external Optum sales.

2 · Offerings

UHC Benefits
Risk & fee medical plans ($344.9bn).
Optum Rx (PBM)
Formulary, mail & specialty ($154.7bn).
Optum Health
Capitated & FFS clinics ($102.0bn).
Optum Insight
Claims IT & analytics ($19.4bn).

3 · Revenue mix

Premiums (78.7%)
$352.2bn underwriting risk.
Products (12.1%)
$54.1bn pharmacy dispensing.
Services (8.2%)
$36.5bn ASO, IT & clinic fees.
Investment inc. (1.1%)
$4.7bn yield on $82.4bn cash & inv.

4 · Segment footing

UHC gross rev.
$344.9bn medical benefit plans.
Optum net rev.
$270.6bn (net of $5.5bn intra-Optum).
Corp. eliminations
−$168.0bn UHC-to-Optum billings.
Consolidated net
$447.6bn external revenue.

5 · Cost to serve

Medical care
$314.0bn claims (89.1% MCR).
Operating & drugs
$107.5bn clinic, PBM & admin.
D&A & interest
$4.4bn D&A + $4.0bn interest.
Low capex
$3.6bn (0.8% of revenue).

6 · What is left

Adj. op. profit
$21.7bn FY25A (4.9% margin).
FY27E rebuild
$29.5bn (6.3% margin).
FCF after SBC
$15.1bn FY25A; $21.0bn FY27E.
Cash returned
$13.5bn div + buybacks FY25A.
88.4%3Q26 MCR (−150bp y/y)
48.3mUHC medical lives (3Q26)
92mOptum Health consumers (3Q26)
393m3Q26 adjusted scripts
12.8%FY26E op. cost ratio guide

Source: SEC FY25 10-K, Q4 FY25 8-K and Q3 FY26 8-K; Penmark model. ASO = administrative services only; FFS = fee-for-service.

Pricing is set annually ahead of medical claims, making underwriting accuracy the main profit swing. CMS fixes MA benchmark rates each April while employers renew in Q4. Medical costs are over 85% variable, leaving little cushion when utilisation spikes.

Working capital runs negative, turning profit quickly into cash despite subsidiary lock-up. Premiums arrive monthly while $39bn of claims payable sit 45 to 50 days on the balance sheet, funding $87bn of cash and investments, though statutory rules retain about $2.4bn a year inside insurance entities.

PART 2 · THE BUSINESS · 5 REVENUE EQUATION & SEGMENT ECONOMICS

Medicare & Retirement drives 38% of revenue, while Optum generates half of operating profit

Exhibit 29: Medical care absorbs $305bn of FY26E revenue, leaving $19bn adjusted net profit
UHC$344.9bnOptum ext.$104.9bnRevenue$449.8bnMedical care$305.0bnCare & opex$118.1bnAdj. EBIT$26.7bnInterest$3.8bnTax, NCI and adjustments, net$4.1bnAdj. net inc.$18.7bn

Source: Company 9M FY26 8-K; Penmark Research FY26E model.

Exhibit 30: Consolidated FY25A revenue of $448bn nets $168bn of internal Optum billings
Medicare & Ret.$171.3bnComm. & State$94.4bnEmployer & Ind.$79.2bnUnitedHealthcare$344.9bn (+15.7%)Optum Rx$154.7bnOptum Health$102.0bnOptum Insight$19.4bnOptum (net)$270.6bn (+7.0%)Corp.eliminations−$168.0bnConsolidatedFY25A$447.6bn (+11.8%)

Source: Company FY25 10-K and Q4 FY25 8-K; Penmark Research.

Exhibit 31: Optum Insight earns a 22% FY27E margin; UHC and Optum Rx carry the scale
8.0%25.0%0.0%3.5%2.0%5.0%Adj. operating margin, FY27ERevenue growth, FY27ECircle area: FY27E revenue ($bn)High-margin coreHigh-margin growthTurnaroundScale growthUHCOptum HealthOptum RxOptum Insight

Source: Penmark Research valuation model.

Exhibit 32: Government programmes and internal transfers dominate revenue mix
Segment / concentration ($bn)FY25AFY27EShareMargin
Segment breakdown (FY27E margin shown)
UHC Medicare & Retirement171.3177.838.2%4.1%*
UHC Community & State94.496.120.7%4.1%*
UHC Employer & Individual79.282.917.8%4.1%*
Optum Rx (gross PBM)154.7161.534.7%3.85%
Optum Health (clinics/VBC)102.095.420.5%4.0%
Optum Insight (IT/claims)19.422.54.8%21.5%
Less: Optum & corp. elim.(173.4)(171.3)−36.9%n.m.
Geographic & payer concentration
US domestic share (ex-S. America)>98%>99%US focusn.m.
CMS + state Medicaid exposure265.7273.858.9%Policy

Source: SEC FY25 10-K; Penmark Research model. *UHC margin is reported at total segment level (4.1% FY27E). FY25A Optum Health and Insight are pre-recast.

PART 2 · THE BUSINESS · 6 THE US MANAGED CARE & SERVICES MARKET

Government programmes fund 39% of $5.3tn US health spend, putting CMS at the centre of margins

Exhibit 33: Private plans, Medicare and Medicaid fund 70% of $5.3tn US health spend
$5.30tn2024 US spendPrivate insurance31%$1.65tnMedicare21%$1.12tnMedicaid18%$0.93tnOut-of-pocket11%$0.56tnOther public & inv.20%$1.04tn

Source: CMS National Health Expenditure Fact Sheet (2024).

Market size and cycle position

US National Health Expenditure (NHE) reached $5.3tn (18% of gross domestic product, GDP) in 2024, growing 5% to 6% a year. Private insurance ($1.65tn), federal Medicare ($1.12tn) and Medicaid ($932bn) pay for $3.7tn of pooled benefits.

Medicare Advantage covers 35m seniors, or 55% of eligible beneficiaries. Growth sits in dual-eligible special-needs plans (D-SNP) and chronic-condition special-needs plans (C-SNP). KFF puts UNH at 26% of all MA members in 2026 (including group and SNP), whereas our RADV model uses UNH’s 7.6m reported MA members (21.1% of ~36m).

The cycle is leaving its 2024–25 trough. The V28 risk-model phase-in, Medicaid redeterminations and commercial hospital and drug inflation above 11% compressed margins and forced 2026–27 plan repricing.

Exhibit 34: UnitedHealth operates across four of five US healthcare profit pools
Plan sponsorsCMS, states, employers$5.3tn US spendHealth benefitsUHC: 48.3m people$344.9bn FY25APBM & specialtyOptum Rx: 23% share$154.7bn FY25ACare deliveryOptum Health: 92m (3Q26)$102.0bn FY25AData & claims ITOptum Insight + Change$19.4bn, 19.2% marginUnitedHealth Group integrated platform ($168bn intersegment)

Source: CMS; company FY25 10-K; Drug Channels Institute; Penmark Research.

Exhibit 35: UNH leads Medicare Advantage at 26% in 2026; top two insurers hold 46%
UnitedHealthHumanaOther MA insurers2026 (35.2m)26%20%54%202529%17%54%

Source: KFF Medicare Advantage 2026 Enrollment Update (March 2026; all-MA incl. group/SNP).

Exhibit 36: Commercial risk lives fell 14% from 4Q24A to 3Q26A as UNH repriced plans
4Q24A3Q26AMedicare Advantage 7.85m7.61m Medicare AdvantageCommercial risk 8.85m7.58m Commercial riskMedicaid 7.44m6.70m Medicaid

Source: Company Q4 FY25 and Q3 FY26 8-K releases.

Regulatory and substitution threats across the value chainFour policy pressures cap profit pools: (1) CMS’s proposed CRUSH rule extrapolating RADV audit recoveries across PY2018–PY2027; (2) separate MA rate-notice proposals to exclude unlinked chart-review diagnoses; (3) client migration to 100% PBM drug-rebate pass-through by 2028; and (4) No Surprises Act independent dispute resolution (IDR) awards raising commercial unit costs.
PART 2 · THE BUSINESS · 7 COMPETITIVE POSITION

Scale and Optum integration lift ROE to 22%, while 9M26 UHC margin sits at 4.8%

Exhibit 37: UNH leads peers on scale, clinics and IT, but carries peak policy risk
UNHELVCVSCIHUMMedicare Advantage scaleIntegrated care deliveryPBM claim volumeClaims IT & dataOperating marginRegulatory exposureNoneHigh riskFairStrongLeading

Source: Company filings; KFF; Drug Channels; Penmark Research.

Exhibit 38: Optum lifts UNH’s 9M26 margin to 7%, above the 4% managed-care peer median
UNH consolidated (9M26)UNH UHC margin (9M26)Elevance HealthCigna GroupHumana6.9%4.8%4.6%4.0%3.5%

Source: Company 9M FY26 8-K; Penmark Research model (latest reported: ELV 4.6%, CI 4.0%, HUM 3.5%).

Exhibit 39: UNH ranks top three in all five lines, though 2026 repricing trimmed risk membership
Segment & peersCustomer choice criteriaUNH rankSource of advantage & durabilityShare & retention trend
Medicare Advantage
HUM, CVS, ELV
Zero-premium benefits, doctor network, Star ratings (≥4 stars). #1 (26% share) Local network density + Optum capitated clinics; ≥69% of members in 4+ Star plans for 2028. KFF all-MA share eased from 29% (2025) to 26% (2026) on plan exits; HUM rose to 20%.
Employer & Individual (E&I)
ELV, CI, CVS
Provider discounts, stop-loss, bundled ASO + PBM + specialty tools. #1 national National provider discount book and integrated Optum Insight and Rx analytics lower employer trend. Risk lives pruned 14% from Dec 2024 to Sep 2026 (8.85m to 7.58m) to defend margin.
Medicaid (C&S)
CNC, MOH, ELV
State bid quality scores, D-SNP integration, behavioural care. Top 3 (6.70m) Multi-state contract record and D-SNP care management cross-sell into Medicare Advantage. Acuity mismatch after redeterminations pushed 2026 core margin near −1%; state rates lag.
PBM (Optum Rx)
CI (ESI), CVS
Net drug cost, specialty pharmacy access, rebate transparency. #3 (23% Rx) Top-3 oligopoly (ESI 31%, CVS 26%, UNH 23% = 80% of US scripts); captive UHC volume anchors scale. 3Q26 scripts 393m vs 414m y/y; moving to 100% rebate pass-through by Jan 2028 (3.8% margin).
Care & Claims IT
CVS/Oak St, Waystar
Capitated risk capability, real-time electronic claims network. #1 clinics & IT 92m Optum Health consumers (3Q26) and Change Healthcare rails create high switching costs. Optum Health Q3 rev −10% y/y on VBC contract exits; Insight 9M26 margin reached 21.3%.

Source: SEC FY25 10-K and Q3 FY26 8-K; KFF (Mar 2026); Drug Channels Institute (2025); Penmark Research.

Why the moat earns 22% ROE without justifying 15x P/E. Capital-light PBM and software earnings lift group ROE 7pp above the 15% peer median, and our peer restatement formula already credits UNH’s 22% ROE in reaching 11.5x.

Scale has shifted from a pure cost edge into an audit magnet. Leading MA at 26% while owning Change Healthcare and 92m-consumer Optum Health leaves UNH exposed to federal RADV audits and DOJ MA coding probes.

PART 2 · THE BUSINESS · 8 MANAGEMENT, GOVERNANCE & CAPITAL ALLOCATION

Top five leaders hold $531m of shares and near-term awards, with 79%–99% equity pay

Exhibit 40: Returning CEO Stephen Hemsley took a $60m five-year option package; four top leaders changed roles in 2024–25
WhoTenure & backgroundHow they are paid (FY25A)What they own (at $349.91)
Stephen HemsleyCEO & Chair of the Board Returned May 202529 yrs at UNH (CEO 2006–17; Chair since 2017; Arthur Andersen). $60.94m total
$0.94m salary/other; $60.00m options (3-yr vest + 2-yr hold).
$467.39m (1,335,742 sh)0.15% of shares; 784x FY25 paid salary (10x req.); 0 Form 4 sales.
Wayne DeVeydtChief Financial Officer Started Sep 2025 (New)<2 yrs at UNH; ex-Bain Capital, Surgery Partners CEO, Anthem CFO. $14.58m total
$2.70m cash/sign-on; $11.50m equity (50% PSUs: EPS & ROE).
$6.88m (19,667 sh)<0.01% of shares; 2 Sep 26 Form 4 tax settlement (−1,209 sh at $399.66).
Timothy NoelCEO, UnitedHealthcare Role Jan 202519 yrs at UNH (joined 2007; ran Medicare & Retirement). $20.20m total
$1.75m cash bonus; $17.00m equity (50% PSUs, 25% opt, 25% RSUs).
$14.94m (42,683 sh*)<0.01%; 15.2x salary; 11 Nov 26 tax settlement (−587 sh at $402.94).
Patrick Conway, M.D.CEO, Optum Role May 2025Joined UNH 2020; ex-Optum Rx CEO, Blue Cross NC CEO, CMS. $19.92m total
$1.75m cash bonus; $17.00m equity (3-yr cum. adj. EPS & avg. ROE).
$26.87m (76,797 sh*)<0.01%; 27.4x salary; Aug 26 open-market sales (−1,669 sh, $661k).
Christopher ZaettaEVP & Chief Legal Officer Role May 2024Leads RADV litigation & DOJ defence; Corporate Secretary. $15.79m total
$0.93m cash bonus; $14.00m equity (50% PSUs: EPS & ROE).
$14.99m (42,829 sh*)<0.01%; 17.7x salary; no Aug–Nov 2026 open-market sales.
Salary & benefitsCash bonus / sign-onEquity (PSUs, options, RSUs)*Includes options exercisable within 60 days of 2 Apr 2026 proxy.

Source: 2026 DEF 14A Proxy Statement (FY25 pay; holdings as of 2 Apr 2026 valued at $349.91); SEC Form 4 filings. EVP = Executive Vice President; PSU = performance stock unit; RSU = restricted stock unit.

Exhibit 41: Insiders disposed of about $1.5m across five Form 4 filings since August 2026
W. DeVeydt (Sep tax)P. Conway (Aug 21 sale)T. Noel (Nov tax)P. Conway (Aug 5 sale)D. Stankiewicz (Aug tax)$483k$456k$236k$205k$94k

Source: SEC Form 4 filings via Signals (Aug–Nov 2026).

Incentive alignment and board governance

Long-term incentives reward per-share earnings and ROE, though option-heavy CEO pay favours upside volatility. Segment chiefs receive half of annual equity in PSUs split equally between three-year cumulative adjusted EPS and average ROE, alongside options and RSUs.

Investor feedback in 2025 prompted governance changes, though Chair and CEO roles stay combined. The board raised CEO ownership rules to 10x salary, added a two-year post-vesting hold on Hemsley’s option grant and has a Lead Independent Director. Officers and directors hold 0.19% of shares under one-share-one-vote rules.

PART 2 · THE BUSINESS · 8 CAPITAL ALLOCATION & GUIDANCE RECORD

Management pivoted from $18bn of FY24–25 M&A to deleveraging toward 40% debt-to-capital

Exhibit 42: UNH generated $69bn of operating cash since FY24A, paying $22bn in dividends
Operating cash$69.0bnDebt & cash draw$1.2bnTotal sources$70.2bnDividends$21.6bnBuybacks$19.6bnAcquisitions$19.5bnCapex$9.5bn

Source: Company FY25 10-K and Q3 FY26 8-K (FY24A–9M FY26A).

Exhibit 43: Repurchases cut diluted shares 5% to FY25A and 11% from FY26E to FY30E
800m850m900m950m1000mFY20AFY22AFY24AFY26EFY28EFY30EActualEstimates801m

Source: Company filings (A); Penmark Research model (E).

Exhibit 44: Initial EPS guidance missed by 45% in FY25A and beat by 15% in FY26E
Actual / PenmarkGuidanceConsensusFY22A EPSFY24A EPSFY25A EPSFY26E EPS$22.19 vs guide $21.10–$21.60$27.66 vs guide $27.50–$28.00$16.35 vs guide $29.50–$30.00$20.73 vs guide $17.75–$20.50

Source: Company earnings releases; Penmark Research model.

Exhibit 45: Buybacks above $282 dilute per-share value, while debt paydown and capex support operations
Use of cashFY24A–9M26A spendForecast policyReturn vs 8.2% CAPM / 10.7% implied CoEAssessment
Dividends $21.62bn (31% CFO) $8.5bn FY27E (+5%/yr) 2.7% next-12m yield; absorbs ~55% of FY27E free cash flow to equity (FCFE, $15.55bn) while cutting leverage. Disciplined
Share repurchases $19.58bn (28% CFO) Surplus FCFE ($7.0bn FY27E) At 14.9x FY27E P/E, retiring shares above our $282 weighted value transfers value to selling holders. Dilutive >$282
Acquisitions (M&A) $19.46bn net cash $0 modelled; debt <40% Built Optum scale (>$100bn goodwill), though South American exits caused an $8.3bn FY24A loss. Paused
Organic capex $9.54bn (0.8% rev) $3.95bn FY27E (0.85%) Funds software, claims automation and clinics (our DCF assumes an 18% terminal return on new equity). Essential

Source: SEC 10-K and 8-K filings; Penmark Research model. CAPM = capital asset pricing model; CoE = cost of equity.

What management’s record means for valueAcross four verifiable initial guidance years (FY22, FY24, FY25, FY26), UNH landed within 10% twice, missed by 45% once (FY25) and beat initial guidance by 15% once (FY26), setting our symmetric 25% bear, 50% base and 25% bull weights.
PART 2 · THE BUSINESS · 9 WHAT MOVES THE STOCK

UNH trades on MCR surprises, CMS policy rules and Optum Health margins, not market beta

We tested seven candidate drivers across ten company and policy events, multi-year total returns, three-year weekly regressions and 75 analyst questions on the last eight calls. Three drivers pass at least three of four tests; market beta explains just 1% of variance.

Exhibit 46: Three operating and regulatory drivers pass three or four empirical tests and anchor our thesis
Confirmed driverWhat moves the stockTests confirmedMarket vs Penmark valueLinked debateNext number to watch
MCR & medical cost trend Quarterly MCR vs guide; 100bp on $356.7bn FY27E UHC rev = ~$3.6bn (vs $14.6bn UHC profit). Four of four tests 1Q25 miss cut −22.5pp; ±50bp UHC margin = ±$18.27/sh in model. Margin normalisation 4Q26 MCR (26 Jan 27): Penmark 91.0% seasonal, FY26E 87.5% vs 88.3%–89.3% initial guide.
CMS MA rates & RADV rule V28 coding phase-in, April MA rate notices and CMS-6098-P CRUSH audit rule. Three of four tests CRUSH rule cut −$62.11/sh (−15.1%); base expected PV is −$4.08/sh ($58/sh gap). Peer multiple gap & RADV clawback CRUSH comments close 19 Jan 27; the 2028 Advance Notice arrives in late January 2027.
Optum Health VBC margins Capitated clinic operating margin vs management’s 6%–8% 2028 target. Three of four tests 4Q25/FY26 guide reset cut −20.0pp; ±50bp Optum Health (OH) margin = ±$4.88/sh in base. Margin normalisation 4Q26 Optum Health margin (26 Jan 27): Penmark −1.1% seasonal, FY26E 3.0%, FY27E 4.0%.

Source: Signals transcripts and KPIs; Yahoo Finance; Penmark Research model.

Exhibit 47: The four largest drops, 14pp to 23pp, came from MCR misses, guidance cuts and the CRUSH proposal
1Q25 MCR miss (Apr 25)4Q25 / 26 guide (Jan 26)CEO & guide pull (May 25)CMS CRUSH rule (Nov 26)2Q25 reset (Jul 25)4Q24 MCR miss (Jan 25)2Q26 raise (Jul 26)1Q26 MCR beat (Apr 26)−22.5pp−20.0pp−18.5pp−13.8pp−7.2pp−5.8pp+1.7pp+7.6pp

Source: Yahoo Finance; SEC 8-K releases (8 largest moves, 4Q24–Nov 2026).

Exhibit 48: The 17–18 Nov drop exceeded our base RADV cost by $58/sh; P/E risk cuts $95/sh
Market price reactionPenmark model impactCMS CRUSH RADV drop($/sh)Peer multiple gap ($/sh)FY27E EPS above Street($/sh)−$62−$4−$95$0$0+$4

Source: Yahoo Finance; Penmark Research valuation model.

Return decomposition confirms multiple compression dominates multi-year total returns. Over five years to 18 Nov 2026, UNH delivered −14.8% total return as −28.4pp of P/E derating outweighed +6.2% EPS growth and +7.4% dividends; over three years (−30.5% total return), EPS fell 15.2% and P/E derating cost 19.5pp.
PART 2 · THE BUSINESS · 9 FACTOR SENSITIVITY, CALL Q&A & DRIVER CLAIMS

Company news explains 86% of variance, and three topics take 81% of analyst Q&A

Exhibit 49: Company and policy news explains 86% of weekly share-price variance
Company-specific & policyHealthcare sector (XLV)Broad market (S&P 500)86.1%12.9%1.0%

Source: Yahoo Finance 3-year weekly regression to 18 Nov 2026 (R² = 0.14).

Exhibit 50: MCR and cost trend took 51% of analyst questions across eight calls
MCR & medical cost trendOptum Health VBCmarginsMA rates, V28 & RADVCommercial membership& ASO mixOptum Rx rebates & GLP-1Capital & balance sheet50.7%16.0%14.7%9.3%6.7%2.7%

Source: Signals transcripts (4Q24–3Q26, n = 75 questions); Penmark coding.

MCR & medical cost trend: Every 50bp UHC margin shift moves base value by $18 a share (±7%)

Market reaction vs model: MCR took 51% of call Q&A (38 of 75 questions; management tone turned hedged in 1H25 before firming in 2Q–3Q26) and drove a 23pp excess drop on 1Q25 results. The share price implies a 6.4% FY27E UHC margin at 11.5x against our 4.1% ($84/sh gap); watch 4Q26 MCR on 26 Jan 2027 (Penmark 91.0%; above 92% risks a 5%–8% drop).

CMS MA rates & RADV policy: Policy risk cuts peer P/E by $95/sh while base RADV cost is $4/sh

Market reaction vs model: Policy took 15% of Q&A (11 questions) and drove a $62/sh (15%) drop on 17–18 Nov 2026 when CMS proposed CRUSH. That exceeded our base RADV cost by $58 a share, or 93% of the drop, yet left UNH at 14.9x vs 11.5x; watch 19 Jan 2027 comments and the 2028 Advance Notice in late January 2027.

Optum Health VBC margin rebuild: Clinic repricing lags management’s 2028 target by 100bp in base

Market reaction vs model: Optum Health took 16% of Q&A (12 questions, hedged on multi-year V28 clinic lag) and contributed to the 20pp drop on 27 Jan 2026. A 50bp Optum Health margin shift moves base value by about $5 a share (±2%), linking to margin normalisation; watch FY27 segment guidance on 26 Jan 2027 (Penmark 4.0%).

Exhibit 51: Four commonly cited factors failed empirical tests and were dropped as primary stock drivers
Candidate tested & droppedTests passedEmpirical evidence from 2024–2026 sampleWhy dropped
Broad equity market (S&P 500)Zero of four3Y weekly OLS R² = 0.01 (5Y monthly raw beta = 0.60); 0% of Q&A.Policy and MCR swamp macro beta.
Interest rates / float yieldZero of fourInvestment income is 1.1% of FY25A revenue ($4.7bn); 0 of 75 call questions.Underwriting spread dwarfs yield.
Commercial membership & ASO mixOne of four9.3% of Q&A (7 questions), but capital-light ASO fees carry minimal MCR volatility.Risk MCR drives profit variance.
Quarterly buyback paceOne of four2.7% of Q&A (2 questions); our model assumes zero Q4 FY26 buybacks during debt paydown.Deleveraging is well telegraphed.

Source: Yahoo Finance weekly returns (Nov 2023–Nov 2026, n = 156 weeks); Signals transcripts (4Q24–3Q26, n = 75 questions; topic coding is Penmark analysis). Limits: multi-factor event days bundle drivers.

PART 3 · THE THESIS · 10 THESIS CHAPTER ONE: PEER VALUATION PARITY
THE CLAIM · RESTS ON CMS POLICY & MCR STOCK DRIVERSRestating managed-care peers for UNH’s 13% growth and 22% ROE supports 11.5x, cutting $95 a share

What the market believes

Bulls treat UNH’s 18.5x five-year average forward P/E as its normal level. At $350, investors pay 14.9x our FY27E EPS (15.1x on the company’s 2027 floor, or 15.5x with RADV added back), assuming integration insulates UNH from the 8.6x to 13.4x multiples paid for peers.

The evidence (three independent sources)

  • Peer 2027 outlooks & ROE formula: Adjusting Elevance (13.4x), Cigna (8.6x) and CVS (9.4x) for UNH’s 13% growth and 22% forward ROE gives 15.9x, 11.4x and 10.4x, a median of 11.4x (11.5x base rule).
  • Segment filings: UHC’s 9M26 margin is 4.8% (3.7% in FY26E) against a 4.0% peer median (ELV 4.6%, CI 4.0%, HUM 3.5%), while $118bn of 9M26 internal billings rules out a sum-of-the-parts valuation.
  • DOJ & DCF cross-check: Our base P/E value equates to a 13% DCF discount rate against 8.2% CAPM, pricing DOJ MA coding probes and MA rate risk.
Exhibit 52: Restating peers for UNH growth and ROE yields an 11.4x median vs 15.1x outlook P/E
ELV restatedUNH current pricePeer raw median (6)CI restated (median)CVS restated15.9x15.1x13.2x11.4x10.4x

Source: Signals; company Q3 2026 calls; Penmark Research model (company-outlook basis).

Exhibit 53: Our base P/E value equates to a 13% DCF discount rate vs 8.2% CAPM
DCF rate at base P/EDCF rate at share priceCAPM cost of equity13.0%10.7%8.2%

Source: Penmark Research DCF discount-rate reconciliation.

Exhibit 54: Adjusting peers with quantified 2027 growth ≤25% sets our 10.5x bear, 11.5x base and 16.0x bull rules
Company (18 Nov price)Price ($)FY27E EPS ($)Raw P/EFY27E gFY25 BV ($)Fwd ROERestated P/EModel role
Elevance Health (ELV)401.0729.9613.4x12.0%195.3815.3%15.9xBull rule (16.0x)
Cigna Group (CI)285.3033.008.6x10.0%155.3221.2%11.4xBase median (11.5x)
CVS Health (CVS)81.348.659.4x13.1%59.1814.6%10.4xBear rule (10.5x)
Centene (CNC, sens.)67.455.2013.0x10.6%*40.4612.9%18.4xExcl.: no 2027 guide
Humana / Molina (avg.)n.m.n.m.21.2x87.2%n.m.n.m.n.m.Excl.: trough rebound
UnitedHealth (UNH)349.9123.1715.1x13.0%103.3022.4%11.5xTarget multiple

Source: Company post-3Q26 outlooks; Penmark Research model (g = 3.5% terminal growth in restatement formula; UNH FY27E P/E is 14.9x on Penmark $23.52 EPS and 15.1x on the $23.17 outlook floor). *CNC guides formally in Feb 2027.

What it is worth

Moving to 11.5x from 15.5x (RADV added back) cuts $95 a share (27% of the share price). A further 1.0x DOJ MA coding derating to 10.5x in bear costs $24 a share.

Signposts & what changes our view

Watch the 6 Apr 2027 MA Final Notice and DOJ filings. Our base multiple rising above 12.1x would move our rating to Hold on its own. We also watch for a clean DOJ coding settlement.

Sensitivity to peer-set compositionEven if Centene (CNC, excluded pending formal February 2027 guidance) were included in the restated set, the peer median multiple would rise from 11.4x to 13.6x, valuing UNH at $317 a share after RADV, still $33 below the $350 share price.
PART 3 · THE THESIS · 11 THESIS CHAPTER TWO: STRUCTURAL MARGIN CEILING
THE CLAIM · RESTS ON MCR COST TREND & OPTUM HEALTH VBC DRIVERSConsolidated adjusted margin rebuilds to 6.3% in FY27E and 7.5% by FY30E, below the 8.7% historical median

What the market believes

Consensus FY27E EPS sits 1% below us, yet the $350 price implies an 8.1% group margin or 6.4% UHC margin at 11.5x. Bulls treat FY25A’s 4.9% margin as brief before returning to the 8.65% FY20A–FY25A median.

The evidence (three independent sources)

  • 9M26 8-K progression: 3Q26 MCR eased to 88.4% (9M26 86.3% vs 89.1% FY25A); Optum Health earned 4.4% in 9M26 ($3.1bn on $70.5bn revenue).
  • 3Q26 call disclosures: Commercial trend above 11% slows employer recovery, core Medicaid sits near −1%, and Optum Health’s 6%–8% goal takes years.
  • PBM & V28 rules: Client shifts to 100% rebate pass-through hold Optum Rx at 3.80% from FY28E, and the V28 risk-model phase-in curbs coding lifts.
Exhibit 55: Segment margins rebuild gradually, staying below the 8.7% FY20–25 median
Adjusted op. marginFY24AFY25AFY27EFY30EImplied / Target
UnitedHealthcare5.4%2.8%4.1%4.9%6.4% at $349.91
Optum Health7.5%2.2%4.0%6.25%6–8% mgmt 28*
Optum Insight23.4%19.2%21.5%22.0%~22% steady
Optum Rx4.4%4.0%3.85%3.80%Rebate pass-thru
Consolidated UNH8.6%4.9%6.3%7.5%8.65% FY20–25 med.
Value per share impact at 11.5x base P/E
Base FY27E (6.35%)EPS $23.52 less $4.08 RADV$266.36Sell (−23.9%)
Norm. FY30E (7.52%)Applied to FY27E revenue$321.19Below $349.91
Hist. median (8.65%)Robustness test (Buy flip)$374.06+15.5% 12m TR

Source: Company filings; Penmark Research model (~7.7% margin from FY31E). *Mgmt targets 6%–8% by 2028; we model 5.0% FY28E and 6.25% FY30E (6.0% bull). TR = total return.

Exhibit 56: UHC and Optum Health rebuild gradually to 5% and 6.5% by FY31E, below past peaks
UHC margin, %FY31E: 5.0%FY24AFY31EOptum Health, %FY31E: 6.5%FY24AFY31EOptum Insight, %FY31E: 22.0%FY24AFY31EOptum Rx, %FY31E: 3.8%FY24AFY31E

Source: Company filings (A); Penmark Research model (E).

What it is worth

The 2.3pp gap between our 6.35% FY27E margin and the 8.65% historical median is worth $108 a share ($266 vs $374). In bear, unpriced medical trend returning UHC’s margin to 3.0% cuts $41 a share.

Signposts & what changes our view

Watch 26 Jan 2027 segment guidance and April’s 1Q27 MCR. Sub-86.5% MCR and Optum Health reaching a 6% operating margin in FY27E–FY28E would support our $428 bull case.

PART 3 · THE THESIS · 12 THESIS CHAPTER THREE: BOUNDED RADV CLAWBACK RISK
THE CLAIM · RESTS ON CMS MA RATES & RADV POLICY DRIVERThe CRUSH audit rule costs about $4 a share in our base case, far below the $62 sell‑off

What the market believes

When CMS released the CRUSH proposed rule (CMS-6098-P), UNH fell from $412 on 16 Nov to $350 on 18 Nov (−$62 a share, or −$56bn across 902m diluted shares). Traders priced full 10-year audit clawbacks plus lasting MA margin damage.

The evidence (three independent sources)

  • CMS-6098-P fiscal math: CMS estimates $9bn per payment year of extrapolated RADV recoveries across PY2018–PY2027 (10 years). At UNH’s 21.1% reported MA enrolment share (vs 26% KFF all-MA share), after-tax 10-year PV is $10.5bn, or $12 a share.
  • 5th Circuit appeal: CMS’s 2023 RADV rule was vacated in N.D. Texas in Sep 2025 and the appeal has been heard in the 5th Circuit; Administrative Procedure Act (APA) challenges push recoupment to late 2027 or beyond.
  • Rate-notice offset: Separate MA rate-notice proposals to exclude unlinked chart reviews in 2028 cost under $2 a share in bear because insurers reprice annual bids.
Exhibit 57: The $62 CRUSH sell-off was 5x full after-tax RADV cost and 15x our $4 base charge
−$80−$60−$40−$20$02-day stockdropDrop beyond100% RADV100% RADVPV65% oddsrule failsBase RADVcharge (35%)−$62.11+$50.45−$11.66+$7.58−$4.08

Source: CMS-6098-P fact sheet; Yahoo Finance; Penmark Research model.

Exhibit 58: Even full RADV enforcement deducts $12 a share; our 35% base case deducts $4 a share
RADV liability build & scenariosBasis / weightTotal ($m)Per share ($)Gap vs $349.91
CMS industry RADV recovery (10 yrs)$9bn / yr × 10 (PY2018–PY2027)90,000n.m.CMS-6098-P est.
UNH MA enrolment share (gross)21.1% MA enrolment share18,990$21.05Pre-tax, undiscounted
After-tax 10-yr PV (100% upheld)Bear (100%)(10,517)($11.66)−$7.58/sh vs base
Penmark base expected RADV PVBase (35%)(3,681)($4.08)+$7.58/sh vs 100%
Extrapolation vacated / withdrawnBull (0%)0$0.00+$4.08/sh vs base
Two-day UNH drop (17–18 Nov 26)902m sh × −$62.11(56,023)($62.11)15.2x base PV

Source: CMS-6098-P; Yahoo Finance; Penmark Research model (21.1% = 7.6m reported UNH MA members / ~36m total members).

What it is worth (counter-evidence to our Sell)

The November CRUSH sell-off exceeded our expected RADV cash cost by $58 a share. Adding back $8 a share relative to full RADV enforcement still leaves UNH overvalued by $84 a share on peer P/E.

Signposts & what changes our view

Public comments close 19 Jan 2027; the 5th Circuit ruling and final rule follow in 2027. Vacating RADV adds $4 a share directly and could lift peer multiples if paired with supportive 2028 MA rates.

Why prospective chart-review limits matter less than P/E contagionUnlike retroactive PY2018–PY2027 audit clawbacks, separate 2028 MA rate-notice proposals on unlinked chart reviews (−$1.67/sh bear impact) arrive before June 2027 bid submissions, allowing UNH to adjust benefits; the larger drag is persistent policy risk holding peers near 11.5x.
PART 4 · THE NUMBERS · 13 TRACK RECORD & QUALITY OF REPORTED NUMBERS

Revenue compounded at about 12% over five years, until FY25A MCR ended an 8%–9% margin run

Exhibit 59: Six-year history shows 8%–9% GAAP margins from FY20A to FY24A before the 4% FY25A trough
US$bn / per shareFY20AFY21AFY22AFY23AFY24AFY25A9M25A9M26A
Revenue ($bn)257.1287.6324.2371.6400.3447.6334.4336.4
Revenue growth y/yn.d.+11.8%+12.7%+14.6%+7.7%+11.8%n.m.+0.6%
GAAP op. earnings ($bn)22.424.028.432.432.319.018.623.5
GAAP op. margin8.7%8.3%8.8%8.7%8.1%4.2%5.6%7.0%
Adj. op. earnings ($bn)n.d.n.d.n.d.n.d.34.421.718.623.2
UHC margin6.2%5.4%5.8%5.8%5.4%2.8%3.5%4.8%
Medical care ration.d.n.d.n.d.n.d.85.5%89.1%88.1%86.3%
Adjusted EPS ($)n.d.19.0222.1925.1227.6616.3514.2218.30
GAAP diluted EPS ($)16.0318.0821.1823.8615.5113.2313.2117.50
FCF-after-SBC / adj. NIn.d.n.d.n.d.n.d.76.6%101.4%n.m.131.5%

Source: SEC 10-K and 8-K filings; Penmark Research model (n.d. = not in sources used; FY20–23 UHC rounded to $0.1bn).

Exhibit 60: Adjusted EPS exceeded GAAP by 78% in FY24A on South America exits, narrowing to 5% by FY27E
Adjusted EPSGAAP EPSAdj. vs GAAP gap (right)$0$10$20$300%20%40%60%80%FY21AFY22AFY23AFY24AFY25AFY26EFY27EFY28EActualEstimates

Source: Company 10-K and 8-K filings (A); Penmark Research model (E).

Growth drivers and cash conversion

Five-year revenue growth of about 12% a year combined premium pricing (6%–7%), MA and Optum volume (4%) and M&A (1%–2%). In 9M FY26A, revenue slowed to 0.6% y/y as UNH shed 0.87m commercial risk lives and 0.83m MA lives y/y (1.27m commercial risk lives since Dec 2024) to restore margins.

Cash conversion stays high, though subsidiary solvency rules trap capital. FCF after SBC converted 77% of adjusted net profit in FY24A ($20bn) and 101% in FY25A ($15bn), while regulated subsidiaries retain about $2.4bn a year.

Exhibit 61: Five accounting, reserve and capital checks show narrowing non-GAAP adjustments
Accounting / reserve itemReported practice & filings evidenceEarnings / cash effectStatus
Medical costs payableClaims payable stood at $39.4bn at 3Q26 (~47 days of care costs), mainly incurred but not reported (IBNR) reserves.Short 45–50 day claim tail limits multi-year surprises.Tracked
Non-GAAP exclusionsExcludes intangible amortisation ($1.61bn FY25A), South America sale loss ($8.31bn FY24A) & cyber/restructuring ($2.75bn FY25A).Gap peaked at +78% in FY24A; narrows to +5% FY27E.Improving
Share-based pay (SBC)$1,018m FY24A, $971m FY25A, $843m 9M26A; added back in GAAP operating cash flow.Model deducts SBC as a cash expense in FCF.Adjusted
Segment realignmentFY26 moves Optum Financial from Optum Health into Optum Insight (FY25A OH recast EBIT $1.45bn vs $2.29bn).Lifts Insight profit; makes raw FY25A/26E margins non-comparable.Disclosed
Goodwill & statutory cashGoodwill, intangibles and PP&E reach $169.1bn at 3Q26; $86.6bn cash & investments back reserves.Distorts P/B and EV/EBITDA; we use P/E & FCFE.Modelled

Source: SEC FY25 10-K and Q3 FY26 8-K; Penmark Research model.

PART 4 · THE NUMBERS · 14 FORECASTS

Revenue accelerates from 0.5% in FY26E to 5% by FY30E as margins rebuild to 7.5%

Exhibit 62: FY27E consolidated revenue grows 3% to $465bn, led by 5% Medicare & Retirement
M&R (+5.0%)$177.8bnC&S (+1.0%)$96.1bnE&I (+3.0%)$82.9bnUnitedHealthcare$356.7bn (+3.4%)Optum Rx(+4.0%)$161.5bnOptum Health(+2.0%)$95.4bnInsight (+5.0%)$22.5bnOptum (net)$273.5bn (+3.4%)Corp.eliminations−$165.5bnConsolidatedFY27E$464.8bn (+3.3%)

Source: Penmark Research model.

Exhibit 63: Medicare & Retirement (+5%–6%) and Optum Health margin rebuild (3% to about 6%) drive our forecast
Segment build ($bn / %)FY25AFY26EFY27EFY28EFY29EFY30EKey driver path
UHC Medicare & Ret.171.3169.3177.8188.4199.7210.7−1.2% FY26E; +5.0% FY27E; +6.0% FY28–29E
UHC Comm. & State94.495.196.198.9102.9107.0+1.0% FY27E post-redeterminations; +4.0% LT
UHC Employer & Ind.79.280.582.986.390.194.2+3.0% FY27E on >11% trend pricing; +4.5% LT
UnitedHealthcare rev.344.9344.9356.7373.6392.8411.9UHC margin: 3.7% → 4.1% → 4.4% → 4.9%
Optum Health rev.102.093.595.4100.1106.1112.5Adj. margin: 3.0% → 4.0% → 5.0% → 6.25%
Optum Insight & Rx net168.7171.1178.1187.5197.5208.1Insight 21.5%–22.0%; Rx 3.85% → 3.80%
Corporate eliminations(168.0)(159.7)(165.5)(174.0)(183.7)(194.0)35.6%–36.0% of consolidated revenue
Consolidated revenue447.6449.8464.8487.2512.7538.6Adj. EBIT ($bn): 26.7 → 29.5 → 33.2 → 40.5
Adjusted EPS ($)16.3520.7323.5227.3531.7936.2115.5% FY27–30E CAGR (inside 13–16% LT)

Source: Company filings; Penmark Research model. CAGR = compound annual growth rate.

Exhibit 64: Departures from Jan 2026 guidance reflect 9M26 actuals
Line itemPeriodGuide / Cons.PenmarkReason for gap
Adj. EPS ($)FY26E≥20.50 / 20.5920.739M $18.30; Q4E $2.39 (FY avg. sh)
Adj. EPS ($)FY27E≥23.17 / 23.2923.52+13.4% y/y (low end 13–16%)
MCR (%)FY26E88.3–89.3%*87.5%9M actual 86.3%; 91.0% Q4E
CFO ($bn)FY26E≥18.0*27.89M actual $25.1bn
Buybacks ($bn)FY26E~2.5*5.039M actual $5.03bn; $0 Q4E
OH marginFY28E6.0–8.0%5.0%Multi-year VBC lag (6% bull)

Source: Company guidance; clearank.com consensus; Penmark Research model (*Jan 2026 initial guide not updated in 3Q26; full-year EPS uses 904m full-year average shares).

Exhibit 65: A 50bp shift in both UHC and Optum Health margins moves value by $23 a share
$243.2$252.3$261.5$270.6$279.8$245.6$254.8$263.9$273.1$282.2$248.1$257.2$266.4$275.5$284.6$250.5$259.7$268.8$277.9$287.1$253.0$262.1$271.2$280.4$289.5UHC margin shift−50bp−25bpBase+25bp+50bpOptum Health shift−50bp−25bpBase+25bp+50bp

Source: Penmark Research model.

Fixed vs variable cost leverage

Over 85% of UnitedHealth’s cost base is variable medical and pharmacy claims. Operating costs are guided near 12.8% of revenue in FY26, so margin recovery from 4.9% in FY25A to 6.8% in FY28E rests on plan repricing and clinic risk control.

Cash, capex & statutory capital

Capex stays light at 0.85% of revenue ($4.0bn in FY27E), while statutory rules retain $2.4bn to $3.8bn a year. After paying down $3.0bn of debt in FY27E to reach 39.7% debt-to-capital, FCFE rises from $15.6bn to $25.8bn by FY30E.

PART 4 · THE NUMBERS · 15 VALUATION (1 OF 2): METHODOLOGY & PEER MULTIPLE ANCHOR

Peer P/E gives a $266 base value; weighted scenarios give our $298 target

Exhibit 66: Base and weighted values sit below $350; bull and historical-median tops clear it
Primary P/E, bear to bullThesis range (base value ±10%)Robustness weighted rangeHistorical median margin P/ECross-check FCFE DCF (8.2% CoE)$0$200$400$600$800$169$428$240$293$240$337$321$374$408$609Price $350Target $298

Source: Penmark Research valuation model. Thesis range = base value ($266) ±10%.

Exhibit 67: Reconciliation from FY27E EPS to our $298 target
Primary P/E & target buildBasis / formulaValue
FY27E adjusted EPSBase model ($20,882m / 888m)$23.52
Target FY27E P/E multipleRestated peer median (11.38x)11.5x
Gross equity value / share11.5 × $23.5168$270.44
Less: expected RADV PV35% × ($10,517m / 902m sh)($4.08)
Primary base value / share−23.9% vs $349.91 price$266.36
Bear (25%) & Bull (25%)$168.75 (10.5x) / $428.07 (16.0x)50% tail
Probability-weighted value0.25×Bear + 0.50×Base + 0.25×Bull$282.39
12m roll-forward factor8.18% CoE − 2.72% next-12m div yield+5.46%
12-month price target−14.9% price; −12.2% total return$297.81

Source: Penmark Research model.

Exhibit 68: Our base multiple gives $266 a share; the top of the grid reaches $345
$197.0$208.2$219.3$230.5$241.7$218.2$230.5$242.8$255.2$267.5$239.3$252.8$266.4$279.9$293.4$260.5$275.2$289.9$304.6$319.3$281.6$297.5$313.4$329.3$345.1FY27E adjusted EPS$21.17$22.34$23.52$24.69$25.87Target P/E9.5x10.5x11.5x12.5x13.5x

Source: Penmark Research valuation model.

Why P/E leads and EV, P/B & sum-of-the-parts fail

Managed-care balance sheets distort enterprise and book multiples. EV/EBITDA fails because $86.6bn of cash and investments at 30 Sep 2026 sits partly against $39.4bn of medical costs payable; P/B fails because M&A created over $100bn of goodwill; and $118bn of 9M26 internal billings rules out a sum-of-the-parts valuation.

Why P/E ($266) and DCF ($537) diverge by 102%

Policy risk lives in peer multiples rather than CAPM beta. UNH’s 0.73 Blume beta yields an 8.2% CAPM cost of equity that omits DOJ MA coding probes and MA benchmark rule risk; our base P/E value equates to a 13.0% DCF discount rate.

Scenario probability weights and limitsOur symmetric 25% bear, 50% base and 25% bull weights reflect UNH’s four-year initial guidance record (one beat above 10%, two within 10% and one miss above 10%). Because a four-year sample cannot pin down tail odds precisely, we test seven standalone sensitivity cases on the next page.
PART 4 · THE NUMBERS · 15 VALUATION (2 OF 2): FCFE DCF, REVERSE DCF & ROBUSTNESS

Matching $350 requires about an 11% discount rate or a 6.4% UHC margin

We cross-check P/E with a 10-year FCFE discounted cash flow (DCF) model through FY35E. We discount equity cash flows at an 8.2% cost of equity rather than a weighted-average cost of capital (WACC, which blends debt and equity costs). Terminal value, at 3.5% growth and an 18% return on new equity, is 66% of gross value. Reverse DCF solves for the single input required to justify the $350 share price.

Exhibit 69: FCFE DCF value spans $416 to $827 across our discount-rate and growth grid
$599.7$540.3$491.4$450.5$415.8$636.3$567.6$512.2$466.6$428.4$682.8$601.3$537.2$485.6$443.0$743.8$644.0$568.2$508.5$460.3$827.2$700.0$607.4$536.8$481.3Cost of equity7.2%7.7%8.2%8.7%9.2%Terminal growth2.5%3.0%3.5%4.0%4.5%

Source: Penmark Research valuation model.

Exhibit 70: The historical median margin reaches Buy; a 1pt lower discount rate reaches Hold
Historical median marginCost of equity (±1.0pp)Beta range (1.00 to 0.60)RADV upheld (100% to0%)Weighted $282Base −$16Med. 8.65% +$92+1pt −$39−1pt +$551.00 −$430.60 +$27100% −$80% +$4

Source: Penmark Research valuation model.

Exhibit 71: Reverse DCF expectations at $350 and seven robustness checks behind our low conviction view
Reverse DCF & robustness testBaseTestedVal ($/sh)12m TRRating & takeaway
Reverse DCF: single input needed to justify $349.91 (other base inputs held)
FY27E P/E on $23.52 EPS (incl. RADV)11.5x15.05x$349.91n.m.+3.55x premium vs peers
FY27E adj. EPS at 11.5x base P/E$23.52$30.78$349.91n.m.+30.9% above base EPS
UHC FY27E margin at 11.5x P/E4.10%6.39%$349.91n.m.+21bp above FY20A peak
Cost of equity in FCFE DCF (3.5% g)8.18%10.70%$349.91n.m.Base P/E equates to 12.98% DCF rate
Model robustness suite (3 of 7 tests change Sell rating → low conviction)
1. As modelled (25 / 50 / 25 weights)8.18%Base$282.39−12.2%Sell (2.2pp below Hold)
2. Cost of equity −1.0pt (P/E scales)8.18%7.18%$337.14+3.4%Flips to Hold
3. Beta at 5Y raw (0.60 vs 0.732)0.7320.600$309.83−4.4%Flips to Hold
4. Hist. median margin (8.65%)6.35%8.65%$374.06+15.5%Flips to Buy (bull risk)
5. Base case alone (100% weight)50% wt100% wt$266.36−17.0%Confirms Sell
6. Cost of equity +1.0pt (P/E scales)8.18%9.18%$243.15−23.3%Confirms Sell
7. Market beta (1.00 vs 0.732)0.7321.000$239.51−24.3%Confirms Sell

Source: Penmark Research model. DOJ coding liability is $0 in the cash bridge as unquantified in filings (carried in our 10.5x bear P/E).

PART 4 · THE NUMBERS · 16 CATALYSTS & MONITORING FRAMEWORK

Seven milestones through 2027 test UNH’s 15x multiple

Exhibit 72: Dated 12-to-18-month catalyst calendar comparing Penmark expectations with Street consensus
DateEvent & driverPenmark expectationMarket / consensusLikely stock move
Dec 2026Investor updateReaffirms ≥$20.50 FY26E & $23.17 FY27E floor.Street $23.29; bulls seek >$24.Flat to −4% on floor
19 Jan 2027CRUSH comments duePlans challenge PY2018–27 RADV extrapolation.15% drop priced full clawback.+2%–4% if softened
26 Jan 20274Q26 & FY27 guide4Q26E EPS $2.39, MCR 91.0%; FY27E $23.52.4Q ~$2.29; FY27E Street $23.29.±5%–8% on MCR
Late Jan 272028 Advance NoticeModest base lift; chart-review curbs proposed.Hopes for post-V28 rate relief.−$1.67/sh if tight
6 Apr 20272028 MA Final NoticeFY28E M&R +6.0%; MA margin 2%–4%.Seeks multi-year rate clarity.Anchors 11.5x P/E
Apr 20271Q27 MCR printTests >11% pricing & 4.0% OH.Smooth step to 6%–8%.−8%–12% if missed
2H 20275th Cir. / RADV rule35% upheld ($4.08/sh PV); APA appeals run.Binary headline sensitivity.+$4 vacated / −$8 full

Source: CMS regulatory calendar; company releases; Penmark Research model.

Exhibit 73: Six catalysts between December 2026 and April 2027 test guidance and CMS policy
Dec 2026Year-end updateFY27 EPS floor ≥$23.1719 Jan 27CRUSH comment deadlinePlans challenge PY18–27RADV26 Jan 274Q26 earnings2027 MA membership &MCRLate Jan2028 MA Advance NoticeChart review & V28 update6 Apr 272028 MA Final RateSets FY28 M&R growthApr 20271Q27 MCR printFirst test of >11% trend

Source: CMS calendar; company releases; Penmark Research.

Exhibit 74: Our adjusted EPS estimates sit about 1% above consensus in FY26E and FY27E
ConsensusPenmarkFY26E Adj. EPS $20.59$20.73 FY26E Adj. EPSFY27E Adj. EPS $23.29$23.52 FY27E Adj. EPS

Source: clearank.com (12 Nov 2026); Penmark Research model.

Exhibit 75: Thesis monitoring framework by stock driver
IndicatorThesis confirmed (Sell)Thesis broken (Upgrade)
Consol. MCRFY26E ≥87.5% & 1Q27 trend ≥11%.FY27E EPS >$24.80 (Hold); watch MCR <86.5%.
Segment EBITFY27E UHC ≤4.2% & OH ≤4.2%.8.65% median margin restored (Buy).
MA & RADV2028 MA notice tight; CRUSH kept.5th Cir. vacates RADV & MA rate >4%.
DOJ & P/EDOJ coding probe lingers; P/E 11.5x.Our base P/E >12.1x (Hold); watch DOJ settlement.

Source: Penmark Research monitoring framework.

What would change our view: Below about $341 the shares sit in our Hold band; so does a base multiple above 12.1x or FY27E EPS above $24.80, each on its own. A 5.5% UHC margin or a 14x to 16x base multiple also gives Hold; only the historical median margin reaches Buy. UNH closed at $330.48 on 19 Nov, after our pricing date, where our target implies a −7% total return. Under our rating policy (p28), a share price can move outside its band before the rating changes, and we will review the rating under that policy.

PART 4 · THE NUMBERS · 17 RISKS

Restoring the 8.7% historical median margin (+$108/sh) leads upside risks; unpriced trend (−$41/sh) leads downside

With a low conviction Sell (−12.2% expected total return, 2.2pp inside the Sell band), the main risks to our rating are upside surprises in margins, discount rates or CMS rules. Five bear-case shocks drive downside to $169.

Exhibit 76: Unpriced medical trend costs $41/sh in bear; Medicaid catch-up adds $19/sh in bull
Medical trend >11% overrunDOJ MA coding settlementCMS CRUSH RADV 100% upheldPBM 100% rebate pass-through2028 MA rate notice cutMA SNP & HMO share gainFY27 EPS guide above StreetCRUSH extrapolation vacatedOptum Health 5% margin in 27Medicaid faster rate catch-up−$40.78−$23.52−$7.58−$5.87−$1.67+$1.44+$2.61+$4.08+$9.91+$18.54

Source: Penmark Research model (modelled per-share value impacts).

Exhibit 77: Upside risks to our Sell call and bear-case operational, legal and policy risks
Risk & directionOdds / weightValue / shMechanism, filings evidence & thesis impact
Upside: 8.65% historical marginRobustness+$107.70Restoring the FY20A–FY25A median 8.65% margin lifts value to $374.06 (+15.5% TR, Buy).
Upside: Full bull re-rating25% bull wt+$161.71Medicaid catch-up (+$18.54), FY27 guide (+$2.61), 5% OH (+$9.91) & 16.0x P/E reach $428.07.
Upside: −1pt CoE or 0.60 betaMacro / Hold+$27–$557.18% CoE lifts weighted value to $337.14 (+3.4% TR, Hold); 0.60 beta gives $309.83 (Hold).
Upside: RADV rule vacatedBull (0% RADV)+$4.085th Circuit strikes down extrapolation without an FFS adjuster, removing our $4.08/sh deduction.
Downside: Trend tops pricing20% prob.−$40.78Specialty drugs, outpatient care and Medicaid acuity push UHC margin back to 3.0% in FY27E.
Downside: DOJ MA coding probe20% prob.−$23.52Civil/criminal MA risk-coding probes curb chart reviews; 1.0x P/E cut to 10.5x costs $23.52/sh.
Downside: CRUSH, PBM & MA35 / 30 / 40%−$15.12100% CRUSH (35%, −$7.58), 2028 PBM pass-through (30%, −$5.87) & 2028 MA notice (40%, −$1.67).
Key-person, cyber & ESGOngoingIn 11.5x P/ECEO S. Hemsley key-person reliance, Change cyber/restructuring ($2.75bn FY25A) & prior-auth rules.

Source: SEC FY25 10-K and 2026 DEF 14A; Penmark Research model.

What would end the thesis and trigger a rating reviewThree shifts would change our call: (1) FY27E EPS guidance above $24.80 or our base multiple rising above 12.1x (either alone moves us to Hold; we also watch MCR below 86.5% and DOJ filings); (2) restoring the 8.65% historical median margin (moving to Buy); or (3) the share price staying below about $341 (it closed at $330.48 on 19 Nov), which puts the 12-month total return inside our −10% to +10% Hold band.
PART 4 · THE NUMBERS · 18 OWNERSHIP & TRADING

Institutions hold 90% of UNH, and none of 26 analysts rate it Sell

Exhibit 78: 21 of 26 Street analysts rate UNH Buy; zero rate it Sell
Buy (21)Hold (5)Sell (0)2150

Source: TickerNerd consensus snapshot (10 Nov 2026).

Exhibit 79: Our $298 target sits $82 below the lowest Street target of $380
Penmark base $266Price, 18 Nov $350Street mean $476Penmark target $298Street low $380Street high $531

Source: 24/7 Wall St. (18 Nov 2026); clearank.com (12 Nov 2026); Penmark Research.

Exhibit 80: Top 10 institutional 13F holders own 42% of shares; several active managers reduced stakes in 3Q26 while Fidelity added
Institution (30 Sep 2026 13F)Sh (m)% S/OVal ($bn)QoQ (m)QoQ %3Q26 activity
1. The Vanguard Group93.2110.40%32.61−0.31−0.3%Passive / trimmed
2. BlackRock, Inc.77.218.62%27.02+0.35+0.5%Passive / added
3. State Street Global Adv.45.705.10%15.99+0.07+0.2%Passive / added
4. FMR LLC (Fidelity)31.063.47%10.87+3.07+11.0%Largest 3Q buyer
5. Capital World Investors28.483.18%9.97−1.41−4.7%Reduced Q3
6. T. Rowe Price Assoc.22.182.48%7.76−1.66−7.0%Reduced Q3
7. Geode Capital Mgmt.20.752.32%7.26−1.01−4.6%Reduced Q3
8. Charles Schwab Inv.20.352.27%7.12+0.52+2.6%Added Q3
9. JPMorgan Chase & Co.17.611.97%6.16−2.63−13.0%Largest 3Q seller
10. Morgan Stanley15.611.74%5.46+0.81+5.5%Added Q3
Top 10 institutions372.1641.53%130.22−2.20−0.6%896.02m basic S/O
Total 13F (3,220 filers)762.2285.07%266.71n.d.n.d.13F coverage

Source: SEC Form 13F filings as of 30 Sep 2026 via Signals (values at 18 Nov $349.91 close; 85.07% 13F coverage vs 89.69% total Yahoo institutional ownership).

Exhibit 81: Trading liquidity, short interest and index profile
MetricReadingAs-of / note
Market cap (18 Nov dil.)$315.6bn902m sh at $349.91 ($313.5bn basic)
3M avg. daily volume5.49m sh (~$1.9bn)Yahoo Finance (to 18 Nov)
CRUSH 2-day volume8.04m / 17.39m sh17 & 18 Nov 26
Short int. / % float13.96m / 1.74%30 Oct (2.41d to cover)
Inst. / insider %89.69% / 0.19%Yahoo / 2026 Proxy
50d / 200d MA$390.64 / $367.9118 Nov (below both MAs)
Current div. rate$9.28/sh (2.65%)Current rate; ex 7 Dec, pay 15 Dec

Source: Yahoo Finance through 18 Nov 2026 (current annualised dividend rate $9.28/sh vs $9.51/sh expected next 12 months).

Positioning and trading profile

Street ratings stay overwhelmingly bullish despite mixed 3Q26 13F flows. Across 26 analysts (10 Nov 2026), 21 rate UNH Buy and none rate it Sell; non-contemporaneous targets span $380 to $531 (median $490 on 12 Nov; mean $476 on 18 Nov), sitting $82 to $233 above our $298 target.

Short interest stood at 1.74% of float (13.96m shares, 2.41 days to cover) on 30 October 2026. During the 17–18 Nov CRUSH sell-off, volume rose to 17.39m shares (3.2x average), leaving UNH below its 50-day ($391) and 200-day ($368) moving averages.

PART 5 · APPENDIX · 19 FINANCIAL MODEL

Linked annual financial model (FY25A–FY30E) and nine-quarter operating progression

Exhibit 82: Consolidated income statement, cash flow, FCFE and balance sheet summary (US$m except per share)
US$m / per shareFY25A9M26AFY26EFY27EFY28EFY29EFY30E
Income statement
Revenue447,567336,447449,847464,769487,209512,700538,566
Adj. operating earnings21,71623,20826,72829,50033,19037,05340,502
GAAP operating earnings18,96423,54427,06429,50033,19037,05340,502
Interest & disposal loss(4,267)(3,089)(4,054)(3,823)(3,850)(3,957)(4,064)
Tax & NCI(2,641)(4,581)(5,274)(5,838)(6,731)(7,583)(8,341)
GAAP net earnings12,05615,87417,73619,83922,60925,51328,098
Adjusted net earnings14,89716,59818,74320,88223,59726,45328,990
Adjusted EPS ($)16.3518.3020.7323.5227.3531.7936.21
GAAP diluted EPS ($)13.2317.5019.6222.3426.2030.6635.09
Diluted avg. shares (m)911906904888863832801
Cash flow & FCFE build (forecast treats SBC as cash cost)
Operating cash flow19,69725,08727,84724,91728,12831,39434,208
Capital expenditure(3,622)(2,421)(3,801)(3,951)(4,141)(4,358)(4,578)
FCF after SBC15,10421,82323,20320,96623,98627,03629,630
FCFE (after reg. capital)n.a.n.a.n.a.15,55021,00123,54425,801
Dividends paid7,9166,1708,2538,5428,7698,8898,990
Share repurchases5,5455,0315,0317,00812,23314,65416,811
Balance sheet & key ratios (period-end; 9M26A = 30 Sep 2026)
Cash & investments82,37286,61385,90988,29091,27594,76898,597
Total assets309,581312,782312,528315,131318,661322,813327,294
Medical costs payable39,33739,35239,32040,66942,59144,77446,958
Total debt78,38974,33174,33171,29571,29571,29571,295
Shareholders’ equity100,090104,129103,907108,197109,804111,774114,071
Adjusted ROE (%)15.0%n.m.18.4%19.7%21.6%23.9%25.7%

Source: SEC filings; Penmark Research model (debt/capital: 43.9% FY25A, 41.7% FY26E, 39.7% FY27E, 38.5% FY30E).

Exhibit 83: Nine-quarter trajectory from Q4 FY24A through Q4 FY26E shows the Q4 FY25 trough and 2026 seasonal curve
Quarterly4Q24A1Q25A2Q25A3Q25A4Q25A1Q26A2Q26A3Q26A4Q26E
Revenue ($bn)100.8109.6111.6113.2113.2111.7112.1112.7113.4
GAAP EBIT ($bn)7.779.105.17*4.320.389.008.006.563.52
Adj. EPS ($)6.817.204.082.922.117.236.384.692.39
MCR (%)87.6%84.8%89.4%89.9%92.4%83.9%n.a.88.4%91.0%

Source: SEC filings; Penmark Research model (*2Q25 implied from 9M25 $18.58bn less 1Q & 3Q; 2Q26 MCR not in model).

Exhibit 84: Segment adjusted operating profit ($m) and period-end risk membership detail
Segment EBIT ($m) & KPIsFY24AFY25A9M26AFY26EFY27EFY28EFY30E
UnitedHealthcare adj. EBIT16,2489,57812,32612,87614,62616,43920,183
Optum Health adj. EBIT7,9302,286*3,0742,8243,8145,0067,032
Optum Insight adj. EBIT4,3933,727*3,4164,7564,8435,3026,184
Optum Rx adj. EBIT5,8366,1254,3926,2726,2166,4427,103
MA / Medicaid / Comm. risk (m)7.8 / 7.4 / 8.88.4 / 7.4 / 8.27.6 / 6.7 / 7.6n.d.n.d.n.d.n.d.

Source: SEC filings; Penmark Research model (*FY25A pre-recast; recast OH $1,449m, Insight $4,564m).

PART 5 · APPENDIX · 20 REFERENCE

Non-GAAP reconciliation, glossary, ratio definitions, peer rules and source cut-offs

Exhibit 85: Reconciliation from GAAP net earnings to adjusted net earnings and adjusted EPS
US$m / per shareFY24AFY25A9M26AFY26EFY27EFY28E
GAAP net earnings to UNH14,40512,05615,87417,73619,83922,609
Plus: intangible amort. (pre-tax)1,6651,6131,0531,4051,3001,235
Plus: tax, cyber & disposal items9,6291,228(329)(398)(257)(247)
Adjusted net earnings25,69914,89716,59818,74320,88223,597
GAAP diluted EPS ($)15.5113.2317.5019.6222.3426.20
Adjusted EPS ($)27.6616.3518.3020.7323.5227.35

Source: UNH Q4 FY25 and Q3 FY26 8-K reconciliations; Penmark Research model.

Glossary

  • MCR: Medical costs divided by premium revenue.
  • MA & V28: Medicare Advantage plans and CMS’s 2024–26 V28 risk-model phase-in.
  • RADV & CRUSH: Risk-coding audits and CMS-6098-P extrapolating PY2018–27 errors.
  • VBC & FFS: Capitated value-based care vs traditional fee-for-service billing.
  • PBM & ASO: Pharmacy benefit manager (Optum Rx) and employer fee-only administration.
  • IBNR: Medical costs incurred by members but not yet reported in claims payable.

Methodology & data cut-offs

We model UNH as an integrated US health insurer and health-services group facing heavy federal regulation and policy risk. Valuation is dated 20 Nov 2026 and priced at the 18 Nov 2026 NYSE close of US$349.91 (US$ issuer; no FX or ADR adjustments). Limits: FY25A Optum segments are pre-recast; FY27E revenue consensus was not found; DOJ liability is $0 in the cash bridge.

Sources: Penmark Research model (20 Nov 2026); SEC 10-K, 10-Q, 8-K, DEF 14A, 13F & Form 4 filings; Yahoo Finance market data (18 Nov 2026); CMS, KFF and Drug Channels statistics.

Exhibit 86: Ratio and KPI definitions
MeasureDefinition in Penmark modelBasis
Adjusted EPSGAAP diluted EPS plus after-tax intangible amortisation and non-operating items.Non-GAAP 8-K
FCF after SBCOperating cash flow less capital expenditure less share-based compensation.Cash flow
FCFEFCF after SBC less statutory capital retained in subsidiaries plus target debt reset.Equity DCF
Adjusted ROEAdjusted net earnings divided by average equity (peer fwd ROE = FY27E EPS / FY25 BVPS).Return ratio
Restated peer P/EPeer FY27E P/E × (UNH g / Peer g) × ((1 − 3.5% / UNH ROE) / (1 − 3.5% / Peer ROE)).Peer formula

Source: Company filings; Penmark Research model.

Exhibit 87: Managed-care peer set and inclusion rules (18 Nov 2026 prices)
Peer (ticker)Business model & inclusion ruleRaw P/EFY27E gRestated
Elevance (ELV)Commercial/Medicaid/MA insurer + Carelon services; included (≤25% growth rule).13.39x12.0%15.89x (Bull)
Cigna Group (CI)Commercial ASO health plan + Evernorth (Express Scripts PBM); included.8.65x10.0%11.38x (Base)
CVS Health (CVS)Aetna insurer + Caremark PBM + Oak Street clinics + retail; included.9.40x13.1%10.40x (Bear)
CNC / MOH / HUMExcluded: CNC lacks 2027 growth guide (18.42x sens.); MOH (+81%) & HUM (+93%) rebound.13.0–21.8x10.6–93%Excluded

Source: Company outlooks; Penmark Research model as of 18 Nov 2026.

PART 5 · APPENDIX · 21 DISCLOSURES

Analyst certification and important disclosures

Ratings

Ratings are based on the total return from the share price to our 12-month price target, including dividends. The price target is weighted across bull, base and bear scenarios.

BuyTotal return to price target above +10%
HoldTotal return to price target from −10% to +10%, inclusive
SellTotal return to price target below −10%

We review ratings at each set of results and whenever the facts change materially. A share price can move outside its band before the rating changes, and targets may not be reached.

Analyst certification

The Penmark Team certifies that (1) the views in this report accurately reflect its views about the subject company and its securities, and (2) no part of its compensation was, is or will be directly or indirectly related to the specific ratings, price targets or views in this report.

Contact

Penmark Research

Questions about our research:
research@penmarkresearch.com

All our research and coverage:
penmarkresearch.com

Basis of preparation

This report uses information publicly available up to its publication date. Share prices are closing prices on the trading day before the publication date, unless stated otherwise. Forecasts, valuations and price targets are Penmark Research’s own, and forecast periods are marked E. Sources are shown beneath each exhibit.

Valuation and price targets

Price targets are based on the valuation methods set out in each report and are weighted across bull, base and bear scenarios. The main risks to each rating and price target are described in the report. Penmark Research updates its coverage after each set of results but is not obliged to update a report at any other time.

Independence and conflicts of interest

Penmark Research is independent. It does not provide investment banking, brokerage, market-making or asset management services, does not trade securities, and does not accept payment from any company for research coverage. Companies do not see or review Penmark Research reports before publication.

No member of the Penmark Team holds a long or short position, directly or through derivatives, in the securities of any company Penmark Research covers.

Regulatory status

Penmark Research publishes general, impersonal investment research on a regular basis. It is not registered as an investment adviser with the US Securities and Exchange Commission or any state securities authority, is not a registered broker-dealer and is not a member of FINRA. Penmark Research does not give advice tailored to any person’s circumstances.

Not investment advice or an offer

This report is for information only. It is not personalised investment advice and is not an offer or solicitation to buy or sell any security or other financial instrument. It does not take into account any reader’s objectives, financial situation or needs. Readers should make their own investment decisions and seek independent professional advice where appropriate.

Forward-looking statements and risk

Forecasts, valuations and price targets are estimates based on assumptions that may prove wrong, and they may not be achieved. Opinions are current as of the publication date and may change without notice. Investing in equities involves risk, including the loss of capital. Share prices can be volatile, and past performance is not a reliable indicator of future results.

Data and sources

Company financials, operating data and filings come from company filings, earnings releases and earnings calls. Market data and any consensus estimates come from third-party sources named beneath the relevant exhibit; consensus figures from aggregators are unofficial. Penmark Research does not use other brokers’ research. Third-party data belong to their providers and may not be extracted from this report.

Accuracy and liability

Information is taken from sources believed to be reliable, but Penmark Research makes no representation or warranty as to its accuracy, completeness or timeliness. To the fullest extent permitted by law, Penmark Research accepts no liability for any loss arising from use of this report. Descriptions of litigation and regulatory matters reflect allegations and public records, not findings, unless stated. If a published report is corrected, the corrected version carries an “Updated” date at penmarkresearch.com.

Distribution and access

Penmark Research reports are available to registered users of penmarkresearch.com. Downloads and programmatic access are governed by the Penmark Research subscription terms. This report is not directed at, or intended for, any person in Singapore or India, and access from those countries is blocked. It is not intended for distribution to, or use by, any person in any jurisdiction where that would be contrary to law or regulation or would subject Penmark Research to registration or licensing requirements there.

Copyright and permitted use

© Penmark Research. All rights reserved. Penmark Research is a trade name of Brightriver Labs. Readers may share a link to this report but may not copy, reproduce, redistribute, sell or use its content, including for text and data mining, without written consent. Contact: research@penmarkresearch.com.

Keep reading

Sign in to Penmark